Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"? (Q39834875)

15 September 2017

title

Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"? (English)

1 reference

Adaptive radiation therapy

15 September 2017

main subject

0 references

author

Danil V Makarov

series ordinal

2

1 reference

15 September 2017

5

Alan W Partin

1 reference

15 September 2017

6

Patrick C Walsh

1 reference

15 September 2017

4

Leslie Mangold

1 reference

15 September 2017

Matthew E Nielsen

1

1 reference

15 September 2017

Elizabeth Humphreys

series ordinal

3

1 reference

15 September 2017

language of work or name

English

0 references

publication date

15 February 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

72

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

389-93; discussion 394-5

1 reference

The value of serum prostate specific antigen determinations before and after radical prostatectomy

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

The PSA nadir that indicates potential cure after radiotherapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

Guideline for the management of clinically localized prostate cancer: 2007 update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.10.053

10.1016/J.UROLOGY.2007.10.053

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference